Wunderman Lands Cancer Drug

NEW YORK Wunderman here has landed consumer-directed creative duties on AstraZeneca Pharmaceuticals’ Faslodex cancer drug after a review, the WPP Group shop confirmed.

AstraZeneca has not advertised Faslodex to consumers before so the assignment is new. Billings were not disclosed, but sources pegged them at $5-10 million.

Wunderman’s work will take the form of print ads and collateral pieces that will appear in doctors’ offices. The shop may also develop interactive ads. Its first campaign is expected this summer.

Faslodex treats postmenopausal women with hormone-receptor positive, metastatic breast cancer that has progressed after therapy with a hormonal treatment, according to www.faslodex.com.

Wunderman, which is said to have bested two other undisclosed agencies in the review, is an AstraZeneca roster shop that already handled two of the company’s other cancer drugs: Arimidex and Casodex/Zoladex.

Other Wunderman clients include Microsoft, Citibank and Hewlett-Packard.